Increased Serum Levels of MIC1/GDF15 Correlated with Bone Erosion in Spondyloarthritis: A Pilot Study

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2018 Dec 22

PMID 30572513

Citations 4

Authors

Yingyu Song

Yang Cui

Xiao Zhang

Haobo Lin

Guangfeng Zhang

Hui Zeng

Yonghan Zeng

Affiliations

Soon will be listed here.

Abstract

Introduction: To assess the association between growth differentiation factor-15 (GDF15) and radiographic features including bone marrow edema and bone erosion in Spondyloarthritis (SpA).

Methods: Patients with SpA (n = 120) receiving treatment in the Guangdong General Hospital, China, between August 2012 and December 2016 were retrospectively included. Serum of patients and healthy controls (n = 30) were collected and GDF15 levels were measured using ELISA. Inflammation was assessed by C-reactive protein (CRP), and magnetic resonance imaging (MRI) of the sacroiliac joint using Spondyloarthritis Research Consortium of Canada score and a method of dichotomy to assess fat metaplasia, bone erosion, and ankylosis. Radiographs of the pelvis were scored using the modified New York (mNY) score.

Results: Serum GDF15 levels were higher in SpA patients compared to controls (503.52 ± 222.92 vs. 190.86 ± 104.18 pg/mL, P < .0001). Patients who suffered from bone erosion on MRI had higher levels of GDF15 (525.72 [186.33, 801.62]vs. 428.06 [255.15, 670.98] pg/mL, P = .0375). There was a positive correlation between serum GDF15 and CRP (r = 0.5442, P < .0001). Moreover, GDF15 levels were related to CRP levels (r = 0.5658, P < .0001) in those X-ray scores were III, according to 1984mNY criteria. Receiver operating characteristic (ROC) analysis showed that GDF15 levels above 501.98pg/mL could predict presence of bone erosion on MRI.

Conclusion: The present study suggested that serum GDF15 levels are higher in SpA patients than in healthy controls. The GDF15 level was correlated with CRP and may be a surrogate biomarker in bone erosion.

Citing Articles

Growth differentiation factor-15 serum concentrations reflect disease severity and anemia in patients with inflammatory bowel disease.

Tonkic A, Kumric M, Akrapovic Olic I, Rusic D, Zivkovic P, Supe Domic D World J Gastroenterol. 2024; 30(13):1899-1910.

PMID: 38659482 PMC: 11036493. DOI: 10.3748/wjg.v30.i13.1899.

Bone Involvement in Rheumatoid Arthritis and Spondyloartritis: An Updated Review.

Orsini F, Crotti C, Cincinelli G, Di Taranto R, Amati A, Ferrito M Biology (Basel). 2023; 12(10).

PMID: 37887030 PMC: 10604370. DOI: 10.3390/biology12101320.

Epicardial adipose tissue thickness and growth differentiation factor 15 in axial spondyloarthritis: A cross-sectional study.

Okcu M, Kocak F, Sas S, Guclu K Saudi Med J. 2022; 43(9):1020-1026.

PMID: 36104054 PMC: 9987668. DOI: 10.15537/smj.2022.43.9.20220304.

Pathophysiological pathways related to high plasma growth differentiation factor 15 concentrations in patients with heart failure.

Ceelen D, Voors A, Tromp J, Van Veldhuisen D, Dickstein K, de Boer R Eur J Heart Fail. 2022; 24(2):308-320.

PMID: 34989084 PMC: 9302623. DOI: 10.1002/ejhf.2424.

References

Hsiao E, Koniaris L, Sebald S, Huynh T, Lee S . Characterization of growth-differentiation factor 15, a transforming growth factor beta superfamily member induced following liver injury. Mol Cell Biol. 2000; 20(10):3742-51. PMC: 85678. DOI: 10.1128/MCB.20.10.3742-3751.2000. View

Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J . Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005; 280(20):19883-7. DOI: 10.1074/jbc.M413274200. View

Ago T, Sadoshima J . GDF15, a cardioprotective TGF-beta superfamily protein. Circ Res. 2006; 98(3):294-7. DOI: 10.1161/01.RES.0000207919.83894.9d. View

Brown D, Moore J, Johnen H, Smeets T, Bauskin A, Kuffner T . Serum macrophage inhibitory cytokine 1 in rheumatoid arthritis: a potential marker of erosive joint destruction. Arthritis Rheum. 2007; 56(3):753-64. DOI: 10.1002/art.22410. View

Kelly J, Lucia M, Lambert J . p53 controls prostate-derived factor/macrophage inhibitory cytokine/NSAID-activated gene expression in response to cell density, DNA damage and hypoxia through diverse mechanisms. Cancer Lett. 2008; 277(1):38-47. DOI: 10.1016/j.canlet.2008.11.013. View

Appel H, Ruiz-Heiland G, Listing J, Zwerina J, Herrmann M, Mueller R . Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2009; 60(11):3257-62. DOI: 10.1002/art.24888. View

Cui Y, Xiao Z, Shuxia W, Zhenjun Z, Hengguo Z, Liangyi F . Computed tomography guided intra-articular injection of etanercept in the sacroiliac joint is an effective mode of treatment of ankylosing spondylitis. Scand J Rheumatol. 2010; 39(3):229-32. DOI: 10.3109/03009740903313613. View

Meadows C, Risbano M, Zhang L, Geraci M, Tuder R, Collier D . Increased expression of growth differentiation factor-15 in systemic sclerosis-associated pulmonary arterial hypertension. Chest. 2010; 139(5):994-1002. PMC: 3087455. DOI: 10.1378/chest.10-0302. View

Dougados M, Baeten D . Spondyloarthritis. Lancet. 2011; 377(9783):2127-37. DOI: 10.1016/S0140-6736(11)60071-8. View

10.

Hinoi E, Ochi H, Takarada T, Nakatani E, Iezaki T, Nakajima H . Positive regulation of osteoclastic differentiation by growth differentiation factor 15 upregulated in osteocytic cells under hypoxia. J Bone Miner Res. 2011; 27(4):938-49. DOI: 10.1002/jbmr.1538. View

11.

Weber U, Pedersen S, Ostergaard M, Rufibach K, Lambert R, Maksymowych W . Can erosions on MRI of the sacroiliac joints be reliably detected in patients with ankylosing spondylitis? - A cross-sectional study. Arthritis Res Ther. 2012; 14(3):R124. PMC: 3446505. DOI: 10.1186/ar3854. View

12.

Korkosz M, Gasowski J, Leszczynski P, Pawlak-Bus K, Jeka S, Kucharska E . High disease activity in ankylosing spondylitis is associated with increased serum sclerostin level and decreased wingless protein-3a signaling but is not linked with greater structural damage. BMC Musculoskelet Disord. 2013; 14:99. PMC: 3639156. DOI: 10.1186/1471-2474-14-99. View

13.

Tsui F, Tsui H, Las Heras F, Pritzker K, Inman R . Serum levels of novel noggin and sclerostin-immune complexes are elevated in ankylosing spondylitis. Ann Rheum Dis. 2013; 73(10):1873-9. DOI: 10.1136/annrheumdis-2013-203630. View

14.

Weber U, Ostergaard M, Lambert R, Pedersen S, Chan S, Zubler V . Candidate lesion-based criteria for defining a positive sacroiliac joint MRI in two cohorts of patients with axial spondyloarthritis. Ann Rheum Dis. 2014; 74(11):1976-82. DOI: 10.1136/annrheumdis-2014-205408. View

15.

Maksymowych W, Wichuk S, Chiowchanwisawakit P, Lambert R, Pedersen S . Development and preliminary validation of the spondyloarthritis research consortium of Canada magnetic resonance imaging sacroiliac joint structural score. J Rheumatol. 2014; 42(1):79-86. DOI: 10.3899/jrheum.140519. View

16.

Tuylu T, Sari I, Solmaz D, Kozaci D, Akar S, Gunay N . Fetuin-A is related to syndesmophytes in patients with ankylosing spondylitis: a case control study. Clinics (Sao Paulo). 2014; 69(10):688-93. PMC: 4221327. DOI: 10.6061/clinics/2014(10)07. View

17.

Hur K . Is GDF15 a Novel Biomarker to Predict the Development of Prediabetes or Diabetes?. Diabetes Metab J. 2014; 38(6):437-8. PMC: 4273029. DOI: 10.4093/dmj.2014.38.6.437. View

18.

Haynes K, Tseng H, Kneissel M, Glant T, Brown M, Thomas G . Treatment of a mouse model of ankylosing spondylitis with exogenous sclerostin has no effect on disease progression. BMC Musculoskelet Disord. 2015; 16:368. PMC: 4662039. DOI: 10.1186/s12891-015-0823-8. View

19.

Weir K . Microbiology: Inflammatory evidence. Nature. 2015; 528(7582):S130-1. DOI: 10.1038/528S130a. View

20.

Cui Y, Zheng J, Zhang X, Zeng H, Luo R . Evaluation of treatments for sacroiliitis in spondyloarthropathy using the Spondyloarthritis Research Consortium Canada scoring system. Arthritis Res Ther. 2016; 18:38. PMC: 4734856. DOI: 10.1186/s13075-016-0916-2. View